Granisetron Kabi

Granisetron Kabi is a prescription intravenous formulation containing the active ingredient granisetron hydrochloride. It belongs to the 5‑HT3 receptor antagonist class and is used as an antiemetic to help control nausea and vomiting associated with chemotherapy and surgery. The product is marketed in the European Union and is supplied only with a healthcare professional’s prescription.

Granisetron Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings. It is commonly used in the following situations:

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) after surgical procedures. - Adjunct therapy for radiation‑induced nausea and vomiting when chemotherapy is also administered. - Use in patients who have experienced inadequate control of nausea with other antiemetics. - Management of nausea and vomiting in patients receiving highly emetogenic cancer treatments.

Granisetron Kabi may cause side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common: - Headache - Constipation - Fatigue or drowsiness - Diarrhea - Dizziness - Injection site discomfort

Serious: - Severe allergic reaction (anaphylaxis, rash, swelling) - Cardiac arrhythmias or QT prolongation - Persistent or worsening nausea and vomiting despite therapy - Severe constipation leading to bowel obstruction

Before using Granisetron Kabi, several precautions should be considered to ensure safe and effective treatment.

- Assess patient history for cardiac disease, especially prolonged QT interval. - Use cautiously in patients with electrolyte disturbances (e.g., low potassium or magnesium). - Monitor for signs of hypersensitivity, particularly after the first dose. - Adjust dose or discontinue if severe constipation or bowel obstruction develops. - Evaluate renal and hepatic function in patients with organ impairment. - Inform patients that the medication is for prevention, not treatment, of established nausea and vomiting.

Granisetron Kabi can interact with other medications, potentially altering its efficacy or safety profile.

Avoid: - Other 5‑HT3 antagonists or drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics). - Strong CYP3A4 inhibitors that may increase granisetron plasma levels.

Use with caution: - Concurrent use of other antiemetics (e.g., dexamethasone, NK1 receptor antagonists) may require dose adjustments. - Medications that affect electrolyte balance, such as diuretics, may increase cardiac risk. - Opioids and sedatives can enhance central nervous system depression. - Anticholinergic agents may exacerbate constipation.